Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

BACKGROUND: Often, patients with primary immunodeficiency diseases (PID), which are marked by the absence or loss of functional antibodies, require lifelong treatment with immunoglobulin (IG) replacement therapy administered either intravenously (intravenous immunoglobulin [IVIG]) or subcutaneously...

Descripción completa

Detalles Bibliográficos
Autores principales: Meckley, Lisa M., Wu, Yanyu, Ito, Diane, Berner, Todd, McCoy, Barbara, Yel, Leman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197164/
https://www.ncbi.nlm.nih.gov/pubmed/32366233
http://dx.doi.org/10.1186/s12865-020-00346-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197164/
https://www.ncbi.nlm.nih.gov/pubmed/32366233
http://dx.doi.org/10.1186/s12865-020-00346-z

Ejemplares similares